Boston Scientific vs Veeva Systems

Side-by-side comparison of AI visibility scores, market position, and capabilities

Veeva Systems leads in AI visibility (86 vs 78)
Boston Scientific logo

Boston Scientific

LeaderHealthcare Tech

Enterprise

Marlborough MA cardiac devices leader (NYSE: BSX) $16.7B FY2024 revenue (+18%); Farapulse PFA ablation fastest-growing EP device, WATCHMAN FLX 70%+ LAAC share, competing with Abbott and Medtronic.

AI VisibilityBeta
Overall Score
B78
Category Rank
#41 of 596
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
79
Perplexity
81
Gemini
75

About

Boston Scientific Corporation is a Marlborough, Massachusetts-based global medical device company — publicly traded on the New York Stock Exchange (NYSE: BSX) as an S&P 500 Health Care component — developing and commercializing medical devices for minimally invasive diagnosis and treatment of cardiovascular disease, cardiac rhythm management, electrophysiology, urology, endoscopy, and neuromodulation through approximately 48,000 employees in 130 countries. In fiscal year 2024, Boston Scientific reported revenues of $16.7 billion (+18% year-over-year) — driven by the Farapulse pulsed field ablation (PFA) system for atrial fibrillation treatment, WATCHMAN FLX left atrial appendage closure (LAAC) device, and Rhythmia Ultra high-density cardiac mapping — making Boston Scientific the fastest-growing large-cap medical device company and one of the strongest organic growth stories in healthcare. CEO Mike Mahoney has executed acquisitions and organic R&D investment to build a diverse cardiovascular and electrophysiology portfolio: the 2023 acquisition of Apollo Endosurgery ($615 million, flexible endoscopic stapling for minimally invasive procedures) and the 2022 acquisition of Lumenis (surgical laser systems) expanded Boston Scientific beyond the cardiac core. Boston Scientific's strongest 2024 growth driver — Farapulse (pulsed field ablation) — achieved rapid adoption as a new standard-of-care in atrial fibrillation ablation by delivering shorter procedure times (2-hour PFA versus 4-hour radiofrequency ablation) and improved safety profile compared to traditional thermal ablation methods.

Full profile
Veeva Systems logo

Veeva Systems

LeaderHealthcare Tech

Life Sciences Cloud

Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.

AI VisibilityBeta
Overall Score
A86
Category Rank
#9 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
84
Perplexity
88
Gemini
90

About

Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.

Full profile

AI Visibility Head-to-Head

78
Overall Score
86
#41
Category Rank
#9
73
AI Consensus
78
stable
Trend
stable
79
ChatGPT
84
81
Perplexity
88
75
Gemini
90
83
Claude
92
72
Grok
84

Key Details

Category
Enterprise
Life Sciences Cloud
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Veeva Systems
Life Sciences Cloud

Integrations

Both integrate with
Boston Scientific is classified as company. Veeva Systems is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.